High dose atorvastatin effects on cardiac biomarkers (24 hours after CABG)

High dose atorvastatin effects on cardiac biomarkers (24 hours after CABG): 80 mg vs 40 mg

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112231024N1

Enrollment

118

Registered

2017-05-06

Start date

2017-05-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease. Atherosclerotic heart disease

Interventions

Intervention 1: patients of group 1 will recieved 80 mg atorvastatin daily for 5 days. Intervention 2: patients of group 2 will recieve 40 mg atorvastatin daily for 5 days.

Treatment - Drugs

patients of group 1 will recieved 80 mg atorvastatin daily for 5 days

patients of group 2 will recieve 40 mg atorvastatin daily for 5 days

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: admission for CABG in Tehran Heart Center. Exclusion criteria: other heart surgeries; COPD; emergent surgeries; liver insufficiency; renal dysfunction ( Cr > 1.5); MI (myocardial infarction) since recent 6 weeks; age > 75 years old.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CKMB and high sensitive cTnT 24 hours after CABG. Timepoint: 24 hours before and 8 and 24 hours after CABG. Method of measurement: CKMB and high sensitive cTnT (ELIZA).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Shekari

Tehran Heart Center

a-shekari@razi.tums.ac.ir+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026